Ashwagandha vs Inositol
Both are commonly discussed for anxiety & stress. Ashwagandha has the stronger research base (moderate evidence), while Inositol is rated weak.
Evidence last reviewed May 2026
Ashwagandha
Adaptogen
Inositol
Carbocyclic Sugar
Evidence
🟡Moderate Evidence
🟠Weak Evidence
Research says
Research agrees
Research agrees
Expert mentions
356
3 recommend
96
1 recommend
Studies
20
referenced
20
referenced
Study dose
300–600mg
The majority of positive RCTs and the meta-analytic evidence supporting stress and anxiety reduction used standardized extracts (e.g., KSM-66 or Sensoril) in the range of 300–600 mg per day, administered as a single dose or split across two doses; higher withanolide standardization (≥5%) is associated with the studied effects.
2000–18000mg
Doses in PCOS and gestational diabetes research typically range from 2,000–4,000 mg/day of myo-inositol, while psychiatric studies (OCD, panic disorder, bipolar) have used up to 18,000 mg/day in divided doses; the D-chiro-inositol form is studied at much lower doses and the optimal myo- to D-chiro ratio (e.g., 40:1) varies by indication.
Best timing
MorningEveningWith food
MorningEveningWith food
Who recommends
Caution
Generally safe
Generally safe
Ashwagandha
Key findings
- ·Multiple RCTs and at least one meta-analysis support statistically significant reductions in perceived stress and anxiety with ashwagandha supplementation, making this the best-evidenced use case.
- ·Cortisol reduction has been reported across several placebo-controlled trials, suggesting a plausible biological mechanism underlying the stress-relief effects.
- ·Doses of 300–600 mg per day of standardized extract, consistent with those used in positive clinical trials, are referenced across the reviewed literature as the studied therapeutic range.
Evidence gaps
- ·Long-term safety data beyond 12 weeks is largely absent, leaving the risk profile for extended supplementation — including liver health — poorly characterized.
- ·Most trials use proprietary or specific extract formulations, making it unclear whether findings generalize to the wide variety of ashwagandha products available to consumers.
Inositol
Key findings
- ·Multiple meta-analyses support myo-inositol (typically 2–4 g/day) for improving metabolic and hormonal parameters in women with PCOS, representing the strongest evidence base for this supplement.
- ·Two meta-analyses of randomized controlled trials indicate that myo-inositol supplementation during pregnancy may reduce the incidence of gestational diabetes mellitus.
- ·Systematic reviews and network meta-analyses suggest inositol may provide modest benefit in Hashimoto's thyroiditis and subclinical hypothyroidism, though evidence is less definitive.
Evidence gaps
- ·Long-term safety and efficacy data are lacking across most indications — most trials are short-duration and do not establish whether benefits persist or whether adverse effects emerge with extended use.
- ·The optimal dose, form (myo-inositol vs. D-chiro-inositol vs. combined), and ratio for specific conditions have not been established through rigorous head-to-head dose-comparison trials.